Over the past decade, we have witnessed the impact immune checkpoint modulators (ICMs) have had on the treatment landscape in several cancers which has resulted in the approval of 19 ICMs, the majority of which are associated with the PD-1/PD-L1 pathway. However, the development of tumor resistance has rendered this form of anti-cancer treatment ineffective to many cancer patients.
Could 4-1BB be the next generation target of choice in cancer immunotherapies?
Download our 4-1BB Landscape Review infographic to see the data behind this target or contact us for more information.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements